Emergent BioSolutions Inc. 2007 10-K Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2007. Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture, and commercialization of immunobiotics (vaccines and therapeutics). The company operates in two segments: Biodefense (centered on its FDA-approved anthrax vaccine, BioThrax) and Commercial (pipeline of vaccines for infectious diseases). The company relies heavily on contracts with the U.S. Department of Defense (DoD) and the Department of Health and Human Services (HHS).
Key Financial Metrics
| Metric | 2007 | 2006 | 2005 |
|---|---|---|---|
| Total Revenues | $182.9 million | $152.7 million | $130.7 million |
| Product Sales (BioThrax) | $169.8 million | $148.0 million | $127.3 million |
| Contracts and Grants | $13.1 million | $4.7 million | $3.4 million |
| Net Income | $22.9 million | $22.8 million | $15.8 million |
| Diluted EPS | $0.77 | $0.93 | $0.69 |
| Cash and Cash Equivalents | $105.7 million | $76.4 million | $36.3 million |
| Total Debt (Principal) | $57.9 million | $33.8 million | $10.5 million |
| Working Capital | $88.6 million | $83.0 million | $29.0 million |
Margins: Gross margin on product sales was approximately 76% in 2007 ($169.8M revenue vs. $40.3M cost of sales). Operating margin was approximately 18% ($33.1M operating income on $182.9M revenue).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20% year-over-year. Product sales rose 15% due to a 41% increase in BioThrax doses delivered, partially offset by a 19% decrease in average sales price per dose (due to discounted pricing for doses with limited shelf life).
- Contract Revenue: Contracts and grants revenue surged 177% to $13.1 million, driven primarily by an $8.8 million milestone payment from HHS for advancing the post-exposure prophylaxis indication for BioThrax.
- Cost of Sales: Increased 67% to $40.3 million, reflecting higher volume and costs associated with an annual production shutdown and waste write-offs.
- R&D Expenses: Increased 19% to $54.0 million, reflecting expanded clinical trials for typhoid and hepatitis B vaccines, and development of anthrax immune globulin.
- Debt: Total debt increased significantly to fund the construction of a new 50,000 sq. ft. manufacturing facility in Lansing, Michigan.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue deriving substantially all revenue from BioThrax sales to the U.S. government. The company is pursuing label expansions for BioThrax (post-exposure prophylaxis, dose reduction, extended expiry) and expanding manufacturing capacity at its new Lansing facility, expected to begin large-scale production in 2008.
Key Risks and Contingencies:
- Government Dependence: The company is highly dependent on U.S. government contracts (DoD and HHS). Future procurement is subject to budgetary constraints and competitive bidding. The DoD may procure BioThrax directly from HHS rather than from Emergent.
- Manufacturing: Delays in FDA approval of the new Lansing facility or the requirement for a human bridging trial could delay revenue growth. The company relies on a single contract manufacturer (Hollister-Stier) for vial filling.
- Regulatory: Approval of product candidates (e.g., anthrax immune globulin, typhoid vaccine) relies on the FDA "animal rule," which carries uncertainty. The company faces ongoing litigation regarding BioThrax safety and liability, though it relies on statutory protections (Safety Act, PREP Act) and government indemnification.
- Competition: Competitors are developing next-generation anthrax vaccines and therapeutics that could reduce demand for BioThrax.
Investor Verification Checklist
- Contract Renewals: Verify the status of future BioThrax procurement contracts with HHS and DoD, specifically regarding the transition of DoD purchases through the Strategic National Stockpile (SNS).
- Manufacturing Capacity: Confirm the timeline for FDA validation and qualification of the new Lansing facility and whether a human bridging trial is required.
- Label Expansion Progress: Monitor FDA decisions on the BioThrax post-exposure prophylaxis indication and dose reduction applications, as these are critical for future pricing and volume.
- Debt Covenants: Review compliance with financial covenants on the $57.9 million debt load, particularly the debt coverage ratio and leverage ratio requirements.
- Legal Exposure: Assess the status of pending product liability lawsuits and the adequacy of insurance coverage and government indemnification provisions.